Abediterol
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Abediterol
- Molecular weight
- 460.52
- Structure (SMILES)
- O=c1ccc2c([C@@H](O)CNCCCCCCOCC(F)(F)c3ccccc3)ccc(O)c2[nH]1
- abediterol
- Abediterol
- Abediterol (2.4 μg)
- Abediterol (2.5 μg)
- Abediterol (4.8 μg)
- abediterol [INN]
- ABEDITEROL [USAN]
- Abediterol [WHO-DD]
- Abediterol 0.05 μg
- Abediterol 0.156 μg
- Abediterol 2.5 μg
- abediterol inn
- abediterol usan
- abediterol who dd
- las 100977
- LAS-100977
- las100977
- LAS100977
- LAS100977 0.313 μg
- LAS100977 0.625 μg
- LAS100977 1.25 μg
- LAS100977 2.5 μg
- CAS registry numbers
- 915133-65-2
- ChEMBL ID
- CHEMBL3039530
- InChIKey
- SFYAXIFVXBKRPK-QFIPXVFZSA-N
- PubChem compound IDs
- 11962616
- FDA ingredient codes (UNII)
- QXA167CM6F
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- abediterol
- Type
- Synthetic organic
- Drug name stem
- -terol
- Action
- Agonist
- Action type
- Agonist
- Target
- β1-adrenoceptor
- Gene symbol
- ADRB1
- Protein identifier
- P08588
- Median affinity
- 7.44
- Affinity units
- pIC50
- Action
- Agonist
- Action type
- Agonist
- Target
- β3-adrenoceptor
- Gene symbol
- ADRB3
- Protein identifier
- P13945
- Median affinity
- 5.52
- Affinity units
- pIC50
- Mechanism
- Beta-2 adrenergic receptor agonist
- Action type
- Agonist
- Target
- Beta-2 adrenergic receptor
- Protein identifier
- P07550
- Action
- Full agonist
- Action type
- FULL_AGONIST
- Target
- β2-adrenoceptor
- Gene symbol
- ADRB2
- Protein identifier
- P07550
- Median affinity
- 9.22
- Affinity units
- pIC50
- Primary target
- Yes
Open Targets mechanisms
- Mechanism
- Beta-2 adrenergic receptor agonist
- Action type
- Agonist
- Target
- Beta-2 adrenergic receptor
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Asthma
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001249
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004979
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005002
- Highest recorded phase
- 2
- NCT01425801
- NCT03273127
- NCT01425814
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 4
- Polar surface area
- 94.58
- Calculated partition coefficient (ALogP)
- 4.23
- Calculated partition coefficient (XLogP)
- 3.1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 13
- Heavy atoms
- 33
- Molecular formula
- C25H30F2N2O4
- Monoisotopic mass
- 460.21736377
- Natural product
- No
- Recorded assays
- 8
- Active assays
- 6
- Confirmatory
- Other
Related records
Trials (15)
- A Single Dose PD & PK Study With Two Formulations of Abediterol in Patients With Asthma
- A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants
- A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.
- Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old.
- Comparative Study of Two Topical Anesthetics Prior to Fractional Nonablative Laser Treatment of the Face
- InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia
- Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers.
- Role of BCAA in Glucose Homeostasis
- Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age
- Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease
- Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population
- Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.
- Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment
- Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
- To Assess the Pharmacokinetics, Safety and Tolerability of Abediterol Administered Once Daily for 9 Days, in Patients With Asthma on Inhaled Corticosteroids
In development for (2)
- Asthma Phase 2
- Chronic obstructive pulmonary disease Phase 2
Targets (1)
- ADRB2 Beta-2 adrenergic receptor agonist